Abstract
Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.
| Original language | English |
|---|---|
| Pages (from-to) | 3185-3192 |
| Number of pages | 8 |
| Journal | Annals of surgical oncology |
| Volume | 25 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2018 Oct 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology
Cite this
}
Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy : Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model. / Park, Eun Jung; Ahn, Junhyun; Gwak, Sang Won; Park, Kyung Su; Baik, Seung Hyuk; Hwang, Sung Joo.
In: Annals of surgical oncology, Vol. 25, No. 11, 01.10.2018, p. 3185-3192.Research output: Contribution to journal › Article
TY - JOUR
T1 - Pharmacologic Properties of the Carrier Solutions for Hyperthermic Intraperitoneal Chemotherapy
T2 - Comparative Analyses Between Water and Lipid Carrier Solutions in the Rat Model
AU - Park, Eun Jung
AU - Ahn, Junhyun
AU - Gwak, Sang Won
AU - Park, Kyung Su
AU - Baik, Seung Hyuk
AU - Hwang, Sung Joo
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.
AB - Background: Carrier solutions play an important role in the distribution, plasma absorption, chemical stability, and solubility of anticancer agents during hyperthermic intraperitoneal chemotherapy (HIPEC). In the current study, lipophilic properties of carrier solutions were evaluated to determine whether they improved anticancer drug absorption rates using mitomycin-C (MMC) or oxaliplatin HIPEC as compared to hydrophilic carrier solutions. Methods: Sprague-Dawley rats were divided into two groups: MMC and oxaliplatin treatment groups. Each group was then further subdivided by carrier solution: Dianeal ® PD-2 peritoneal dialysis solution, 5% dextrose solution and 20% lipid solution (Lipision ® ). HIPEC was performed over 60 min at 41–42 °C using the anticancer drugs MMC (35 mg/m 2 ) or oxaliplatin (460 mg/m 2 ). The plasma area under the curve (AUC; AUC plasma ), peritoneal AUC (AUC peritoneum ), and peritoneal/plasma AUC ratios were compared among HIPEC carrier solutions. Results: Plasma drug concentrations were significantly different among carrier solutions, varying by time. In contrast, peritoneal drug concentrations did not change with carrier solution. In the MMC group, the peritoneal/plasma AUC ratio of a lipid solution was three times higher than Dianeal ® (p < 0.001). In the oxaliplatin group, the peritoneal/plasma AUC ratio was significantly different between carrier solutions (p = 0.046). Although the oxaliplatin AUC peritoneum did not vary (p = 0.941), the AUC plasma of a lipid solution was lower than that of 5% dextrose solution (p = 0.039). Conclusions: The lipid carrier solution increases the peritoneal/plasma AUC ratio and decreases plasma absorption rates. However, further study is required before clinical uses, considering its pharmacologic properties and possible risks after HIPEC.
UR - http://www.scopus.com/inward/record.url?scp=85050356622&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050356622&partnerID=8YFLogxK
U2 - 10.1245/s10434-018-6628-x
DO - 10.1245/s10434-018-6628-x
M3 - Article
C2 - 30027459
AN - SCOPUS:85050356622
VL - 25
SP - 3185
EP - 3192
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 11
ER -